These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18928375)

  • 21. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
    Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
    Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
    Lopez-Cortes LF; Valera-Bestard B; Gutierrez-Valencia A; Ruiz-Valderas R; Jimenez L; Arizcorreta A; Terrón A; Viciana P
    Clin Pharmacol Ther; 2008 Nov; 84(5):573-80. PubMed ID: 18596682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
    Kneteman NM; Howe AY; Gao T; Lewis J; Pevear D; Lund G; Douglas D; Mercer DF; Tyrrell DL; Immermann F; Chaudhary I; Speth J; Villano SA; O'Connell J; Collett M
    Hepatology; 2009 Mar; 49(3):745-52. PubMed ID: 19072827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of circulating HCV recombinant form RF1_2k/1b in blood serum of patients by real-time RT-PCR.
    Akimov IA; Timofeev DI; Mavzyutov AR; Ivanov MK
    Klin Lab Diagn; 2021 Mar; 66(2):122-128. PubMed ID: 33734647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program.
    Karchava M; Chkhartishvili N; Sharvadze L; Abutidze A; Dvali N; Gatserelia L; Dzigua L; Bolokadze N; Dolmazashvili E; Kotorashvili A; Imnadze P; Gamkrelidze A; Tsertsvadze T
    Hepatol Res; 2018 Jan; 48(1):36-44. PubMed ID: 28258606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of hepatitis C virus natural recombinant RF1_2k/1b strain among intravenous drug users in Uzbekistan.
    Kurbanov F; Tanaka Y; Avazova D; Khan A; Sugauchi F; Kan N; Kurbanova-Khudayberganova D; Khikmatullaeva A; Musabaev E; Mizokami M
    Hepatol Res; 2008 May; 38(5):457-64. PubMed ID: 18034826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg.
    Kalinina O; Norder H; Mukomolov S; Magnius LO
    J Virol; 2002 Apr; 76(8):4034-43. PubMed ID: 11907242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phylogenetic analysis of a circulating hepatitis C virus recombinant strain 1b/1a isolated in a French hospital centre.
    Morel V; Ghoubra F; Izquierdo L; Martin E; Oliveira C; François C; Brochot E; Helle F; Duverlie G; Castelain S
    Infect Genet Evol; 2016 Jun; 40():374-380. PubMed ID: 26444584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.
    Chen R; Kobewka M; Addison W; Lachance G; Tyrrell DL
    PLoS One; 2016; 11(1):e0147007. PubMed ID: 26765841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.
    Dimova RB; Talal AH
    J Hepatol; 2010 Sep; 53(3):418-20. PubMed ID: 20561707
    [No Abstract]   [Full Text] [Related]  

  • 35. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia.
    Pimenov N; Kostyushev D; Komarova S; Fomicheva A; Urtikov A; Belaia O; Umbetova K; Darvina O; Tsapkova N; Chulanov V
    Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b.
    Raghwani J; Thomas XV; Koekkoek SM; Schinkel J; Molenkamp R; van de Laar TJ; Takebe Y; Tanaka Y; Mizokami M; Rambaut A; Pybus OG
    J Virol; 2012 Feb; 86(4):2212-20. PubMed ID: 22114341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form.
    Schuermans W; Orlent H; Desombere I; Descheemaeker P; Van Vlierberghe H; Geerts A; Verhelst X; Reynders M; Padalko E
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NS5A sequences of hepatitis C virus genotype 1 and interferon resistance: where are we?
    Germanidis G; Metallidis S; Lazaraki G; Pawlotsky JM; Nikolaidis P
    J Infect Dis; 2008 Jul; 198(1):154-5. PubMed ID: 18544013
    [No Abstract]   [Full Text] [Related]  

  • 39. [New perspectives in the treatment of viral hepatitis C: pegylated interferon alpha].
    Alric L; Cacoub P
    Rev Med Interne; 2001 Oct; 22(10):922-5. PubMed ID: 11695314
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent evidence of underestimated circulation of hepatitis C virus intergenotypic recombinant strain RF2k/1b in the Rhône-Alpes region, France, January to August 2014: implications for antiviral treatment.
    Ramière C; Tremeaux P; Caporossi A; Trabaud MA; Lebossé F; Bailly F; Thélu MA; Nana J; Leroy V; Morand P; André P; Larrat S
    Euro Surveill; 2014 Oct; 19(43):. PubMed ID: 25375898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.